NEW YORK, April 4 (GenomeWeb News) - Evotec said today that it will partner with the University of Cincinnati and Cincinnati Children's Hospital to screen drug targets and cells against chemical compounds.
As part of the agreement, Cincinnati's Computational Medicine Center has purchased from Evotec Technologies a $2.8-million ultra-high-throughput screening system, including cellular imaging components. The CMC is a research collaboration between UC and Cincinnati Children's Hospital that is funded by Ohio Third Frontier and the National Institutes of Health.
The screening system will be housed at UC's Genome Research Institute, and will serve as a core facility for UC, Cincinnati Children's, and eventually other Ohio-based researchers, Evotec said.
Evotec, based in Hamburg, Germany, also said that it will establish US operations for its Evotec Technologies unit in Cincinnati to support the project. Evotec Technologies is the tools division of drug-discovery firm Evotec, and markets ultra-high-throughput screening systems, as well as confocal high-content imaging systems and cell-handling devices.